Predictive impact of RNF43 mutation (mut) in patients (pts) with pMMR/MSS BRAF V600E mutated metastatic colorectal cancer (mCRC) treated with target therapy (TT) or chemotherapy (CT)

被引：0

作者：

Germani, Marco Maria

Moretto, Roberto

Montana, Javier Ros

Intini, Rossana

Ghelardi, Filippo

Vetere, Guglielmo

Toledo, Rodrigo De Almeida

Bergamo, Francesca

Randon, Giovanni

Elez, Elena

Lonardi, Sara

Oldani, Simone

Giordano, Mirella

Rossini, Daniele

Bravo, Walter Ferrari

Ricagno, Gianmarco

Ugolini, Paola Vignali Clara

Fontanini, Gabriella

Cremolini, Chiara

机构：

[1] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy

[2] Azienda Osped Univ Pisana, Unit Med Oncol 2, Pisa, Italy

[3] Azienda Osped Univ Pisana, Unit Med Oncol 2, Pisa, Italy

[4] Vall dHebron Inst Oncol VHIO, Dept Med Oncol, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain

[5] IRCCS, Dept Oncol, Med Oncol 1, Veneto Inst Oncol IOV, Padua, Italy

[6] Fdn IRCCS Ist Nazl Tumori Milano, Dept Med Oncol, Milan, Italy

[7] Vall dHebron Univ Hosp, Barcelona, Spain

[8] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy

[9] Univ Pisa, Dept Surg Med Mol Pathol & Crit Area, Pisa, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3569

引用

页数：1

共 50 条

[1] Predictive impact of RNF43 mutation (mut) in pMMR/MSS BRAFV600E-mutated metastatic colorectal cancer (mCRC) patients (pts) treated with target therapy (TT) or chemotherapy (CT)
Germani, M.
Moretto, R.
Ros, J.
Intini, R.
Ghelardi, F.
Vetere, G.
Toledo, R.
Bergamo, F.
Randon, G.
Elez, E.
Lonardi, S.
Oldani, S.
Giordano, M.
Rossini, D.
Bravo, W. Ferrari
Ricagno, G.
Vignali, P.
Ugolini, C.
Fontanini, G.
Cremolini, C.
ANNALS OF ONCOLOGY, 2023, 34 : S176 - S176
[2] Survival of patients (pts) with BRAF V600E mutated metastatic colorectal cancer (mCRC) treated with systemic therapy in a real-world setting
Gotz, Moritz
Kasper, Stefan
Paul, Andreas
Markus, Peter
Schumacher, Brigitte
Albers, David
Rosery, Vivian
Laue, Katharina
Zaun, Gregor
Kostbade, Karina
Pogorzelski, Michael
Schmid, Kurt Werner
Schildhaus, Hans-Ulrich
Wiesweg, Marcel
Schuler, Martin
Virchow, Isabel
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 65 - 66
[3] Predictive Impact of RNF43 Mutations in Patients With Proficient Mismatch Repair/Microsatellite Stable BRAFV600E-Mutated Metastatic Colorectal Cancer Treated With Target Therapy or Chemotherapy
Moretto, Roberto
Germani, Marco Maria
Ros, Javier
Daniel, Francesca
Ghelardi, Filippo
Vetere, Guglielmo
Giordano, Mirella
Toledo, Rodrigo De Almeida
Bergamo, Francesca
Randon, Giovanni
Elez, Elena
Lonardi, Sara
Pietrantonio, Filippo
Vignali, Paola
Rossini, Daniele
Matito, Judit
Ugolini, Clara
Fontanini, Gabriella
Masi, Gianluca
Cremolini, Chiara
JCO PRECISION ONCOLOGY, 2023, 7
[4] Prognostic impact of depth of response (DpR) and early tumour shrinkage (ETS) in patients (pts) with BRAF V600E mutated (mut) metastatic colorectal cancer (mCRC) receiving targeted therapy (TT) as second-line treatment
Vetere, Guglielmo
Germani, Marco Maria
Bensi, Maria
Antoniotti, Carlotta
Lonardi, Sara
Passardi, Alessandro
Ghelardi, Filippo
Calegari, Maria Alessandra
Borelli, Beatrice
Santucci, Sara
Intini, Rossana
Cristarella, Eleonora
Persano, Mara
Puccini, Alberto
Lavacchi, Daniele
Noto, Laura
Zichi, Clizia
Giampieri, Riccardo
Salati, Massimiliano
Cremolini, Chiara
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[5] RNF43 mutation is associated with aggressive tumor biology along with BRAF V600E mutation in right-sided colorectal cancer
Matsumoto, Akio
Shimada, Yoshifumi
Nakano, Mae
Oyanagi, Hidehito
Tajima, Yosuke
Nakano, Masato
Kameyama, Hitoshi
Hirose, Yuki
Ichikawa, Hiroshi
Nagahashi, Masayuki
Nogami, Hitoshi
Maruyama, Satoshi
Takii, Yasumasa
Ling, Yiwei
Okuda, Shujiro
Wakai, Toshifumi
ONCOLOGY REPORTS, 2020, 43 (06) : 1853 - 1862
[6] THE IMPACT OF BRAF V600E MUTATION AND MICROSATELLITE INSTABILITY ON OVERALL SURVIVAL (OS) IN METASTATIC COLORECTAL CANCER (MCRC)
Parikh, A.
Li, B.
Lamarre, N.
Abraham, A.
Parzynski, C.
Vieira, M. C.
VALUE IN HEALTH, 2022, 25 (07) : S463 - S463
[7] BRAF V600E mutation is a predictive indicator of upfront chemotherapy for stage IV colorectal cancer
Morikawa, Tatsuya
Inada, Ryo
Nagasaka, Takeshi
Mori, Yoshiko
Kishimoto, Hiroyuki
Kawai, Takashi
Umeda, Yuzo
Mishima, Hideyuki
Goel, Ajay
Fujiwara, Toshiyoshi
ONCOLOGY LETTERS, 2018, 15 (02) : 2195 - 2201
[8] Molecular characterization of microsatellite stable (MSS) colorectal cancer (CRC) patients with a BRAF V600E mutation
van der Pol, Ymke
Yilma, Binyam
Morris, Van K.
Chao, Calvin
Harris, Michelle
Guinney, Justin
Kopetz, Scott
CANCER RESEARCH, 2024, 84 (06)
[9] Real-world data of patients (pts) with BRAF V600E-mutated (mt) metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTDeTPI)
Ros Montana, F. J.
Garcia-Galea, E.
Mugarza, P. G.
Comas, R.
Martini, G.
Balconi, F.
Salva Ballabrera, F.
Baraibar Argota, I.
Saoudi Gonzalez, N.
Rodriguez Castells, M.
Alcaraz, A.
Garcia Rodriguez, A.
Alonso-Orduna, V.
Tabernero, J.
Elez Fernandez, M. E.
ANNALS OF ONCOLOGY, 2024, 35 : S43 - S43
[10] BRAF V600E-mutated Colorectal Neuroendocrine Carcinoma Effectively Treated with a Chemotherapy Protocol for BRAF-mutated Metastatic Colorectal Cancer
Owaki, Seira
Mori, Yoshinori
Nakai, Shunsuke
Maeda, Hideki
Imazu, Mitsuki
Tomita, Yusaku
Kanaiwa, Hiroki
Yamaguchi, Ayana
Kitagawa, Mika
Hirano, Atsuyuki
Kimura, Yoshihide
Tsuchida, Kenji
Kataoka, Hiromi
INTERNAL MEDICINE, 2024, 63 (14) : 1995 - 1999

← 1 2 3 4 5 →